Evaluation of a Toolkit to Improve Cardiovascular Disease Screening and Treatment for People With Diabetes
- Conditions
- Diabetes MellitusCardiovascular Disease
- Interventions
- Other: ToolkitOther: Control
- Registration Number
- NCT01411865
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Brief Summary
Diabetes is a common and serious chronic disease. However, there is a large gap between the level of care that people should receive (based on research and guidelines) and the level of care they actually receive. With the release of their 2008 Clinical Practice Guidelines, the Canadian Diabetes Association has a strategy to improve heart disease screening and treatment for people with diabetes. This study will evaluate whether the strategy works. The focus of the strategy was to give all family physicians in Canada a Toolkit in June 2009 to help them delivery better care for their diabetic patients. In Ontario, only half of doctors received this Toolkit. We will compare the quality of care received by diabetic patients whose doctors received this Toolkit versus those who doctors did not.
- Detailed Description
A cardiovascular disease Toolkit was developed by the Canadian Diabetes Association and mailed to family physician with the Spring/Summer 2009 edition of the newsletter, Canadian Diabetes. The Toolkit was packaged in a brightly-coloured box with Canadian Diabetes Association branding, and contained: 1) an introductory letter from the Chair of the practice guidelines' Dissemination and Implementation Committee; 2) an eight page summary of selected sections of the practice guidelines targeted towards primary care physicians; 3) a four page synopsis of the key guideline elements pertaining to cardiovascular disease risk; 4) a small double-sided laminated card with a simplified algorithm for cardiovascular risk assessment, vascular protection strategies and screening for cardiovascular disease; and 5) a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool and a list of recommended risk reduction strategies.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 933789
- Alive on 1 July 2009 with prevalent diabetes
- Age <= 39
- Residing in long-term care
Secondary Analysis:
- Analysis will be repeated using all people alive on 1 July 2009 without prevalent diabetes using the same exclusion criteria, to determine the spill-over effect of the Intervention on physicians' other patients.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intervention Toolkit - Control Control -
- Primary Outcome Measures
Name Time Method Death or non-fatal myocardial infarction Up to 10 months
- Secondary Outcome Measures
Name Time Method Cardiac stress test or nuclear imaging Up to 10 months Ambulatory cardiology or internal medicine visit Up to 10 months Death, non-fatal myocardial infarction or non-fatal stroke Up to 10 months Death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for unstable angina or transient ischemic attack Up to 10 months Hospitalization for myocardial infarction or unstable angina Up to 10 months Death Up to 10 months Coronary angiography Up to 10 months Prescription for insulin Up to 10 months Hospitalization for myocardial infarction Up to 10 months Hospitalization for stroke Up to 10 months Electrocardiogram Up to 10 months Prescription for angiotensin converting enzyme inhibitor or angiotensin receptor blocker Up to 10 months Prescription for at least three classes of antihypertensive agents Up to 10 months Prescription for nitrate Up to 10 months Hospitalization for stroke or transient ischemic attack Up to 10 months Prescription for at least two classes of antihypertensive agents Up to 10 months Prescription for any glucose-lowering drug Up to 10 months Coronary revascularization procedure Up to 10 months Prescription for at least one class of antihypertensive agent Up to 10 months Prescription for statin Up to 10 months
Trial Locations
- Locations (1)
Institute for Clinical Evaluative Sciences
🇨🇦Toronto, Ontario, Canada